3D Systems(DDD) - 2022 Q3 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Revenue for Q3 2022 was $132.3 million, a decrease of 15.3% year-over-year. Excluding divestitures and unfavorable FX impact, revenue increased by 2.7% compared to the prior year [40][41] - Gross profit margin was 39.8%, down from 41.2% in the prior year, attributed to inflationary impacts and changes in product mix [49] - Adjusted EBITDA was negative $0.3 million for Q3 2022, compared to $11.6 million for Q3 2021, reflecting various operational challenges [51] Business Line Data and Key Metrics Changes - Revenue for the Industrial Solutions segment was flat year-over-year but increased nearly 9% in constant currency, driven by strong demand in energy and commercial space applications [16][46] - Healthcare Solutions segment revenue decreased by 6.6% year-over-year and 3.5% in constant currency, primarily due to a significant decline in dental market sales [16][46] - Strong growth was noted in the Medical Devices business, particularly in orthopedic and surgical instrumentation, despite the overall decline in the Healthcare segment [47][48] Market Data and Key Metrics Changes - The U.S. dollar's strength negatively impacted financial performance, with over $8 million in headwinds related to currency fluctuations [41] - Demand in the Americas remained robust, contrasting with pressures faced in Europe due to geopolitical tensions and economic uncertainty [17] - The dental market experienced a significant decline in spending, particularly in orthodontic products, due to reduced consumer confidence and discretionary spending [11][19] Company Strategy and Development Direction - The company is focusing on operational efficiency and profitability while investing in new technology platforms to support growth [8][54] - A strategic acquisition of dp polar was completed to enhance capabilities in high-speed mass production of customized components [20][21] - The company has restructured into two market-facing business units, Industrial Solutions and Healthcare Solutions, to better address market-specific applications [13][14] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging macroeconomic environment, including inflation and supply chain disruptions, but expressed confidence in long-term growth as consumer spending rebounds [7][8] - The company expects the dental market to recover eventually, although the timeline remains uncertain due to macroeconomic factors [19][46] - Management emphasized the importance of maintaining a strong balance sheet and cash position to support future growth initiatives [53][56] Other Important Information - The company ended the quarter with $609 million in cash and short-term investments, a decline of approximately $180 million since the end of 2021 [53] - The company views 2022 as an investment year, focusing on targeted investments in high-potential growth areas [54] Q&A Session Summary Question: OpEx guidance for the year - The company expects OpEx to be in the range of $240 million to $245 million for the year, with a sequential increase due to the full run rate of dp polar expenses and higher sales commissions [58][59] Question: Rationale for carving out Systemic Bio as a standalone business - The decision was made to foster a startup mentality and to protect valuable IP associated with the new technology, focusing on selling the product rather than the printers [60][62] Question: Demand for materials versus machines - There is a trend of customers using existing assets more heavily, leading to increased material demand while printer sales have declined due to economic uncertainty [65][66]